A Multicenter, Double-blind, Randomized, Parallel Group Study to Assess the Effect of NCX4016 vs Placebo on Walking Distance in Patients With Peripheral Arterial Occlusive Disease at Leriche-Fontaine Stage II.

Trial Profile

A Multicenter, Double-blind, Randomized, Parallel Group Study to Assess the Effect of NCX4016 vs Placebo on Walking Distance in Patients With Peripheral Arterial Occlusive Disease at Leriche-Fontaine Stage II.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2011

At a glance

  • Drugs NCX 4016 (Primary)
  • Indications Embolism and thrombosis; Peripheral arterial occlusive disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jan 2011 Last checked against ClinicalTrials.gov record.
    • 07 Dec 2010 Official title, actual initiation date (September 2003) and trial investigator (Gresele P) added as reported by ClinicalTrials.gov.
    • 07 Dec 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health [NCT01256775]).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top